Phase II study of weekly 4'-epidoxorubicin in patients with metastatic squamous cell cancer of the cervix : an EORTC Gynaecological Cancer Cooperative Group Study

In this study 24 patients with metastatic cervical cancer were treated with a weekly bolus injection of 4'-epidoxorubicin at a dose of 12.5 mg/m2. All patients were followed until disease progression. Toxicity was generally absent or very mild. Only 1 patient (4%) had a partial remission lasting 23 weeks and 9 patients (38%) had stable disease with a median duration of 13 weeks (range 7-36). 4'-Epidoxorubicin at this dose and schedule is not active in metastatic squamous cell carcinoma of the cervix.

Medienart:

Artikel

Erscheinungsjahr:

1992

Erschienen:

1992

Enthalten in:

Zur Gesamtaufnahme - volume:29A

Enthalten in:

European journal of cancer (Oxford, England : 1990) - 29A(1992), 1 vom: 16., Seite 147-8

Sprache:

Englisch

Beteiligte Personen:

van der Burg, M E [VerfasserIn]
Monfardini, S [VerfasserIn]
Guastalla, J P [VerfasserIn]
de Oliveira, C [VerfasserIn]
Renard, J [VerfasserIn]
Vermorken, J B [VerfasserIn]

Themen:

3Z8479ZZ5X
Clinical Trial
Clinical Trial, Phase II
Epirubicin
Journal Article

Anmerkungen:

Date Completed 29.12.1992

Date Revised 18.07.2019

published: Print

Citation Status MEDLINE

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM012602817